{"nctId":"NCT00805766","briefTitle":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","startDateStruct":{"date":"2008-12"},"conditions":["Crohn's Disease"],"count":39,"armGroups":[{"label":"TA-650","type":"EXPERIMENTAL","interventionNames":["Drug: TA-650"]}],"interventions":[{"name":"TA-650","otherNames":["Infliximab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with Crohn's disease\n* Patients who have relapsed with symptoms associated with Crohn's disease within 8 weeks in spite of maintenance treatment with 5mg/kg REMICADE every 8 weeks, and who are judged to be showing an insufficient response to the previous treatment by their physician\n\nExclusion Criteria:\n\n* Severe intestinal strictures (which may have an effect on the number of loose stools or diarrhea or dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy), a diagnosis of short bowel syndrome, or previous stoma surgery\n* The presence of significant internal fistula (possibility that surgery might be needed, etc.) is confirmed\n* A history of a serious infusion reaction to REMICADE\n* Pregnant, lactating, and probably pregnant women\n* Patients who have participated in other trials and have been administered other investigational products within 12 weeks before consent\n* Patients judged to be inadequate to participate in this study by their physician","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period","description":"To confirm the decrease in median CDAI at week 8 by ≥ 50 points compared to the CDAI score at week 0 in the increased dose period. In the indication of CDAI change, decrease in CDAI was expressed by positive numbers. CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI scores generally range from 0 to 600 points. Clinical remission = CDAI \\< 150 points. Moderate disease = CDAI 220 - 450 points. Severe disease = CDAI \\> 450 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI at Each Evaluation Time Point in the Increased Dose Period","description":"CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI scores generally range from 0 to 600 points. Clinical remission = CDAI \\< 150 points. Moderate disease = CDAI 220 - 450 points. Severe disease = CDAI \\> 450 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"296.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210.5","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI Remission Rates at Each Evaluation Time Point in the Increased Dose Period","description":"CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI scores generally range from 0 to 600 points. Clinical remission = CDAI \\< 150 points. Moderate disease = CDAI 220 - 450 points. Severe disease = CDAI \\> 450 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI Change at Each Evaluation Time Point in the Increased Dose Period","description":"To confirm the decrease in median CDAI at week 8 by ≥ 50 points compared to the CDAI score at week 0 in the increased dose period. In the indication of CDAI change, decrease in CDAI was expressed by positive numbers. CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI scores generally range from 0 to 600 points. Clinical remission = CDAI \\< 150 points. Moderate disease = CDAI 220 - 450 points. Severe disease = CDAI \\> 450 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Concentration of TA-650 at Each Time Point","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody to TA-650 Determination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":45},"commonTop":["DNA antibody positive","Nasopharyngitis","Oropharyngeal pain","Headache","Influenza"]}}}